WC500185968
WC500185968
WC500185968
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
15.1.2. Bosutinib – BOSULIF (CAP)<br />
<br />
Evaluation of a PSUSA procedure<br />
Regulatory details:<br />
PRAC Rapporteur: Martin Huber (DE)<br />
Administrative details:<br />
Procedure number(s): EMEA/H/C/002373/PSUSA/10073/201409<br />
MAH(s): Pfizer Limited<br />
15.1.3. Brentuximab vedotin – ADCETRIS (CAP)<br />
<br />
Evaluation of a PSUSA procedure<br />
Regulatory details:<br />
PRAC Rapporteur: Sabine Straus (NL)<br />
Administrative details:<br />
Procedure number(s): EMEA/H/C/002455/PSUSA/10039/201408<br />
MAH(s): Takeda Pharma A/S<br />
15.1.4. Cobicistat – TYBOST (CAP)<br />
<br />
Evaluation of a PSUSA procedure<br />
Regulatory details:<br />
PRAC Rapporteur: Rafe Suvarna (UK)<br />
Administrative details:<br />
Procedure number(s): EMEA/H/C/002572/PSUSA/10081/201408<br />
MAH(s): Gilead Sciences International Ltd<br />
15.1.5. Cobicistat, elvitegravir, emtricitabine, tenofovir disoproxil – STRIBILD (CAP)<br />
<br />
Evaluation of a PSUSA procedure<br />
Regulatory details:<br />
PRAC Rapporteur: Rafe Suvarna (UK)<br />
Administrative details:<br />
Procedure number(s): EMEA/H/C/002574/PSUSA/10082/201408<br />
MAH(s): Gilead Sciences International Ltd<br />
15.1.6. Crizotinib – XALKORI (CAP)<br />
<br />
Evaluation of a PSUSA procedure<br />
Regulatory details:<br />
PRAC Rapporteur: Arnaud Batz (FR)<br />
Administrative details:<br />
Procedure number(s): EMEA/H/C/002489/PSUSA/10042/201408<br />
MAH(s): Pfizer Limited<br />
Pharmacovigilance Risk Assessment Committee (PRAC)<br />
EMA/PRAC/257790/2015 Page 72/89